ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Alzheimers Dis Parkinsonism 2019, Vol 9(4): 472
  • DOI: 10.4172/2161-0460.1000472

Clinical Experience with Plasma Progranulin as a Biomarker in a Dementia Cohort

Estrella Gómez-Tortosa1*, María Ruggiero1, Pablo Agüero1, Andrea Gómez1, Cristina Prieto-Jurczynska2, Julián Pérez-Pérez3, M. José Sainz1 and Rosa Guerrero-López4
1Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain
2Department of Neurology, Hospital Infanta Elena, Madrid, Spain
3Secugen SL, Madrid, Spain
4Instituto de Investigación Sanitarias Fundación Jiménez Díaz (IIS-FJD) and CIBERER, Madrid, Spain
*Corresponding Author : Estrella Gómez-Tortosa, Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain, Tel: +34 91 5504800, Email: egomezt@fjd.es

Received Date: Jun 22, 2019 / Accepted Date: Jul 31, 2019 / Published Date: Aug 07, 2019

Abstract

Background: Decreased plasma progranulin levels are a specific marker in screening for Frontotemporal Lobar Degeneration (FTLD) caused by mutations in the GRN gene.
Objective: To describe the performance of this biomarker in clinical practice.
Methods: Using a commercial kit (AdipoGen Inc), we analysed progranulin plasma levels in 436 samples from 240 cases with FTLD phenotypes, 122 with Alzheimer type dementia, 20 with Lewy body type dementia, 15 with a psychiatric phenotype and frontotemporal atrophy, plus 39 cognitively-preserved elderly controls. The GRN gene was sequenced in cases with lower plasma levels. Clinical variables were correlated with plasma levels in cases with GRN mutations.
Results: Eight probands with FTLD phenotypes (3% of all FTLD cases, 12% of FTLD with autosomal dominant family history) and plasma levels below 70 ng/ml were found to carry seven different GRN mutations. The frequency of mutation-positive cases increased to 6% when considering only FTLD cases with asymmetric atrophy, though applying this criterion would have omitted two diagnosed cases. Few false positive cases (n=5) were due to technical errors, and no false negatives (70 to 90 ng/ml) were detected. In the 60 to 70 ng/ml interval, both carriers and non-carriers were found when pulling all procedures together, although they never overlapped in a single assay. None of the cases with non-FTLD
phenotypes had GRN mutations. Plasma levels did not correlate with mutation type, age of onset, or disease stage. Asymptomatic carriers had low levels even decades before the expected age at disease onset.
Conclusion: Progranulin plasma levels are a reliable biomarker to detect the small percentage of FTLD GRNmutation carriers in our cohort, though they are not useful for clinical follow-up.

Keywords: Biological markers; Frontotemporal dementia; Plasma; Progranulin levels; GRN mutations

Citation: Gómez-Tortosa E, Ruggiero M, Agüero P, Gómez A, Prieto-Jurczynska C, et al. (2019) Clinical Experience with Plasma Progranulin as a Biomarker in a Dementia Cohort. J Alzheimers Dis Parkinsonism 9: 472. Doi: 10.4172/2161-0460.1000472

Copyright: © 2019 Gómez-Tortosa E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top